The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
- Advertisement -
APLICATIONS
Benchmark raises $225M in special funds to double down on Cerebras
Benchmark Capital has been an investor in the Nvidia rival since 2016.
